DK2771329T3 - Nye disubstituerede 3,4-diamino-3-cyclobuten-1,2-dion-forbindelser til anvendelse i behandlingen af chemokin-formidlede sygdomme - Google Patents

Nye disubstituerede 3,4-diamino-3-cyclobuten-1,2-dion-forbindelser til anvendelse i behandlingen af chemokin-formidlede sygdomme Download PDF

Info

Publication number
DK2771329T3
DK2771329T3 DK12791825.8T DK12791825T DK2771329T3 DK 2771329 T3 DK2771329 T3 DK 2771329T3 DK 12791825 T DK12791825 T DK 12791825T DK 2771329 T3 DK2771329 T3 DK 2771329T3
Authority
DK
Denmark
Prior art keywords
methyl
radical
amino
atom
enylamino
Prior art date
Application number
DK12791825.8T
Other languages
English (en)
Inventor
Laurence Clary
Patricia Rossio
Marlène Schuppli-Nollet
Branislav Musicki
Jean-Guy Boiteau
Jérã´Me Aubert
Original Assignee
Galderma Res & Dev
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Galderma Res & Dev filed Critical Galderma Res & Dev
Application granted granted Critical
Publication of DK2771329T3 publication Critical patent/DK2771329T3/da

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/14—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing three or more hetero rings
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/52—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/34—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide
    • A61K31/341—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having five-membered rings with one oxygen as the only ring hetero atom, e.g. isosorbide not condensed with another ring, e.g. ranitidine, furosemide, bufetolol, muscarine
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/38—Heterocyclic compounds having sulfur as a ring hetero atom
    • A61K31/381—Heterocyclic compounds having sulfur as a ring hetero atom having five-membered rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/40—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil
    • A61K31/4025—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with one nitrogen as the only ring hetero atom, e.g. sulpiride, succinimide, tolmetin, buflomedil not condensed and containing further heterocyclic rings, e.g. cromakalim
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P11/00—Drugs for disorders of the respiratory system
    • A61P11/06—Antiasthmatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/04—Antipruritics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/06—Antipsoriatics
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P19/00—Drugs for skeletal disorders
    • A61P19/02—Drugs for skeletal disorders for joint disorders, e.g. arthritis, arthrosis
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/14—Radicals substituted by nitrogen atoms not forming part of a nitro radical
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/04—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members
    • C07D307/10—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having no double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/16—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D307/00—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom
    • C07D307/02—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings
    • C07D307/34—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members
    • C07D307/38—Heterocyclic compounds containing five-membered rings having one oxygen atom as the only ring hetero atom not condensed with other rings having two or three double bonds between ring members or between ring members and non-ring members with substituted hydrocarbon radicals attached to ring carbon atoms
    • C07D307/54—Radicals substituted by carbon atoms having three bonds to hetero atoms with at the most one bond to halogen, e.g. ester or nitrile radicals
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D407/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00
    • C07D407/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings
    • C07D407/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having oxygen atoms as the only ring hetero atoms, not provided for by group C07D405/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D409/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms
    • C07D409/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings
    • C07D409/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having sulfur atoms as the only ring hetero atoms containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Epidemiology (AREA)
  • Immunology (AREA)
  • Pulmonology (AREA)
  • Dermatology (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Rheumatology (AREA)
  • Transplantation (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Furan Compounds (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)

Claims (9)

  1. (1) hvor R5 og X har den efterfølgende angivne betydning, R3 står for en heteroaromatisk cyklus, som svarer til den følgende formel (d):
    id) hvor R7, Y og Z har den efterfølgende angivne betydning, hvor det præciseres, at cyklus (d) eventuelt kan bære flere R7-grupper, identiske eller forskellige, hvor det samlede antal for sådanne R7-grupper højst er lig med antallet af atomer, der kan substitueres fra cyklussen; R4 står for en aromatisk cyklus, der svarer til den følgende formel (t):
    (t) hvor R8, R9, R10, R11 og R12 harden efterfølgende angivne betydning, R5 står for et hydrogenatom, et fluoratom, et alkylradikal med 1 til 5 carbona-tomer eller et fluor- eller perfluoralkylradikal med 1 til 5 carbonatomer, R6 står for et hydrogenatom, et -COOtBu- eller -COOBn-radikal, R7 står foret halogenatom, et R16-, -CF3-, -COR16-, -OR16-, -NR16R17-, -N02-, -CN-, -S02R16-, -S02NR16R17-, -NR16COR17-, -CONR16R17-, -NR16C02R17- eller -C02R16-radikal, R8 står for et hydrogenatom, et -OH-, -SH-, -CONHOR16-, -C0NR160H-, -NR16R17-, -S03H-, -OCOR16-, -NHS02R16-, -S02NR16R17-, -NHCOR16-, -CONR16R17-,-NR16C02R17-, -NHS02NR16R17-, -C02R16-, pyrrolyl-, imidazolyl-, triazolyl eller tetrazolylradikal, R9, R10, R11 og R12 er identiske eller forskellige og er uafhængigt udvalgt i gruppen bestående af et hydrogenatom, et halogenatom, et alkyl-, alkoxy- -CF3-, -OCF3-, - OH-, -N02-, -CN-, -S02R16-, -S02NR16R17-, - NR16COR17-, -NR16C02R17-, -CONR16R17-, -C0R16- eller -C02R16-radikal, eller også når to af radikalerne R9, R10, R11 og R12 befinder sig i ortho-position på den aromatiske cyklus (t), så kan de sammen med den forbindelse, som forbinder dem, danne en aryl-, heteroaryl-, cycloalkyl- eller heterocy-cloalkylcyklus R15 står for et hydrogenatom, et -OH-, -S02R16-, -COR16-, -C02R16-, aryl-, heteroaryl-, arylalkyl-, heteroarylalkyl-, alkyl-, cycloalkyl eller cycloalkylalkyl-radikal, R16 og R17 er identiske eller forskellige og er uafhængigt udvalgt i gruppen bestående af et hydrogenatom, et aryl-, heteroaryl-, arylalkyl-, heteroarylalkyl-, alkyl-, fluoral kyl radikal, som har fra 1 til 5 carbonatomer, cycloalkyl- eller cy cl oal kyl al kyl rad i kal, en -CH2COOR18-gruppe, hvor R18 står for et alkylra-dikal med 1 til 5 carbonatomer, eller også når R16 og R17 er bundet til det samme nitrogenatom, danner de en heterocyklus med mellem 3 og 7 led og omfatter eventuelt et eller to hete-roatomer, der er udvalgt blandt oxygen, svovl og nitrogen ud over det fælles nitrogenatom, til hvilket de er bundet, hvor heterocyklussen kan substitueres med en alkylgruppe med 1 til 5 carbonatomer eller en -COOR18-gruppe, hvor R18 står for et alkylradikal med 1 til 5 carbonatomer; X står for et oxygenatom, et svovlatom eller et nitrogenatom, der er substitueret med et radikal R6, Y står for et oxygenatom, et svovlatom eller et nitrogenatom, der er substitueret med et radikal R15, og Z står for et carbon- eller nitrogenatom.
    (1) (2) (3) hvor R5, R7a, X og X' har den efterfølgende angivne betydning, R3 står for en aromatisk eller heteroaromatisk cyklus, der er udvalgt i gruppen bestående af de cyklusser, som svarer til de følgende formler (a), (b) og (riY
    hvor R7, R7a, Y og Z har den efterfølgende angivne betydning, hvor det præciseres, at cyklusserne (a), (b) og (d) eventuelt kan bære forskellige R7- grupper, identiske eller forskellige, hvor det samlede antal for sådanne R7-grupper højst er lig med antallet af atomer, der kan substitueres fra cyklussen; R4 står for en aromatisk eller heteroaromatisk cyklus, der er udvalgt i gruppen bestående af de cyklusser, som svarer til de følgende formler (p), (q), (t), (z), (ad), (ag) og (ah): <p> <q)
    (t) {z)
    (ad) (ag) (ah) hvor R8, R9, R10, R11, R12, R13 og R15 står for en aromatisk eller heteroaromatisk cyklus, der er udvalgt i gruppen bestående af de cyklusser, som svarer til de følgende formler, R5 står for et hydrogenatom, et fluoratom, et alkylradikal med 1 til 5 carbona-tomer eller et fluor- eller perfluoralkylradikal med 1 til 5 carbonatomer, R6 står for et hydrogenatom, et -COOtBu- eller -COOBn-radikal, R7 står for halogen, et R16-, -CF3-, -COR16-, -OR16-, -NR16R17-, -N02-, -CN, -S02R16-, -S02NR16R17-, -NR16COR17-, -CONR16R17-, - NR16C02R17- eller -C02R16-radikal, R7a står for et hydrogen- eller alkylradikal med 1 til 5 carbonatomer, R8 står for et hydrogenatom, et -OH-, -SH-, -CONHOR16-, -C0NR160H-, -NR16R17-, -S03H-, -OCOR16-, -NHS02R16-, -S02NR16R17-, -NHCOR16-, -CONR16R17-, -NR16C02R17-, -NHS02NR16R17-, -C02R16-, pyrrolyl-, imidazolyl-, triazolyl- eller tetrazolylradikal, R9, R10, R11 og R12 er identiske eller forskellige og er uafhængigt udvalgt i gruppen bestående af et hydrogenatom, et halogenatom, et alkyl-, alkoxy- -CF3-, -OCF3-, - OH-, -N02-, -CN-, -S02R16-, -S02NR16R17-, - NR16COR17-, -NR16C02R17-, -CONR16R17-, -C0R16- eller -C02R16-radikal, eller også når to af radikalerne R9, R10, R11 og R12 befinder sig i ortho-position på en aromatisk eller heteroaromatisk cyklus, der er udvalgt i gruppen bestående af de cyklusser, der svarer til formlerne (p), (q), (t), (z), (ad), (ag) og (ah) ovenfor, så kan de sammen med den forbindelse, som forbinder dem, danne en aryl-, heteroaryl-, cycloalkyl- eller heterocycloalkylcyklus, R13 er udvalgt fra gruppen bestående af et hydrogenatom, et halogenatom, et alkyl-, -CF3-, -OCF3-, -OH-, -SH-, -CN-, -S02R16-, -S02NR16R17-, -NHS02NR16R17-, -NR16R17-, -NR16CONR16R17-, -NR16COR17-, -NR16C02R17-, -CONR16R17-, -COR16- eller -C02R16-radikal, R15 står for et hydrogenatom, et -OH-, -S02R16-, -COR16-, -C02R16-, aryl-, heteroaryl-, arylalkyl-, heteroarylalkyl-, alkyl-, cycloalkyl eller cycloalkylalkyl-radikal, R16 og R17 er identiske eller forskellige og er uafhængigt udvalgt i gruppen bestående af et hydrogenatom, et aryl-, heteroaryl-, arylalkyl-, heteroarylalkyl-, arylalkyl-, heteroarylalkyl-, alkyl-, f I uo ral kyl rad i kal, som har fra 1 til 5 car-bonatomer, cycloalkyl- eller cycloalkylalkylradikal, en -CH2COOR18-gruppe, hvor R18 står for et alkylradikal med 1 til 5 carbonatomer, eller også når R16 og R17 er bundet til det samme nitrogenatom, danner de en heterocyklus med mellem 3 og 7 led og omfatter eventuelt et eller to hete-roatomer, der er udvalgt blandt oxygen, svovl og nitrogen ud over det fælles nitrogenatom, til hvilket de er bundet, hvor heterocyklussen kan substitueres med en alkylgruppe med 1 til 5 carbonatomer eller en -COOR18-gruppe, hvor R18 står for et alkylradikal med 1 til 5 carbonatomer; X og X', identiske eller forskellige, står for et oxygenatom, et svovlatom eller et nitrogenatom, der er substitueret med et radikal R6, Y står for et oxygenatom, et svovlatom eller et nitrogenatom, der er substitueret med et radikal R15, og Z står for et carbon- eller nitrogenatom.
    (1) (2) (3) (4) hvor R5, R7a, X og X' har den efterfølgende angivne betydning, R3 står for en aromatisk eller heteroaromatisk cyklus, der er udvalgt i gruppen bestående af de cyklusser, som svarer til de følgende formler (a) til (o):
    ti) (k). (0 (m)
    (π) (ο) hvor R7, R7a, Υ og Ζ har den efterfølgende angivne betydning, idet det skal præciseres, at cyklusserne (a) til (o) kan eventuelt bære flere identiske eller forskellige R7-grupper, hvor det samlede antal af sådanne R7-grupper er højst lige med antallet af atomer, som kan substitueres med cyklussen; R4 står for en aromatisk eller heteroaromatisk cyklus, der er udvalgt i gruppen bestående af de cyklusser, som svarer til de følgende formler (p) til (z) og (aa) til (ak):
    (ag) (ah) (aj) (aj) (a^ hvor R7, R8, R9, R10, R11, R12, R13, R14 og R15 har den efterfølgende angivne betydning, R5 står for et hydrogenatom, et fluoratom, et alkylradikal med 1 til 5 carbona-tomer eller et fluor- eller perfluoralkylradikal med 1 til 5 carbonatomer, R6 står for et hydrogenatom, et -COOtBu- eller -COOBn-radikal, R7 står for et halogen, et -R16-, -CF3-, -COR16-, -OR16-, -NR16R17-, -N02-, -CN-, - S02R16-, -S02NR16R17-, -NR16COR17-, -CONR16R17-, -NR16C02R17- eller -C02R16-radikal, - R7a står for hydrogenradikal eller et alkylradikal med 1 til 5 carbonatomer, R8 står for et hydrogenatom, et halogenatom, et -OH-radikal, et -SH-, -CONHOR16-, -CONR160H-, -NR16R17-, -S03H-, -OCOR16-, -NHS02R16-, -S02NR16R17-, -NHCOR16-, -CONR16R17-, -NR16C02R17-, - NHS02NR16R17-, -C02R16-, pyrrolyl-, imidazolyl-, triazolyl- eller tetrazolyl-radikal, R9, R10, R11 og R12 er identiske eller forskellige og er uafhængigt udvalgt fra gruppen bestående af hydrogen, et halogenatom, et alkyl-, alkoxy-, -CF3-, -OCF3-, -OH-, -N02-, -CN-, -S02R16-, -S02NR16R17-, -NR16COR17-, -NR16C02R17-, -CONR16R17-, -COR16- eller -C02R16-radikal, eller også når to af radikalerne R9, R10, R11 og R12 befinder sig i ortho-position på en aromatisk eller heteroaromatisk cyklus, der er udvalgt i gruppen bestående af de cyklusser, der svarer til formlerne (p) til (z) og (aa) til (ak) ovenfor, så kan de sammen med den forbindelse, som forbinder dem, danne en aryl-, heteroaryl-, cycloalkyl- eller heterocycloalkylcyklus, R13 og R14 er identiske eller forskellige og er uafhængigt udvalgt i gruppen bestående af et hydrogenatom, et halogenatom, et alkyl-, -CF3-, -OCF3-, -OH-, -SH-, -CN-, -S02R16-, -S02NR16R17-, -NHS02NR16R17-, -NR16R17-, -NR16CONR16R17-, -NR16COR17-, -NR16C02R17-, - CONR16R17-, -COR16- eller -C02R16-radikal, R15 står for et hydrogenatom, et -OH-, -S02R16-, -COR16-, -C02R16-, aryl-, heteroaryl-, arylalkyl-, heteroarylalkyl-, alkyl-, cycloalkyl- eller cycloalkylalkyl-radikal, R16 og R17 er identiske eller forskellige og er uafhængigt udvalgt i gruppen bestående af et hydrogenatom, et aryl-, heteroaryl-, arylalkyl-, heteroarylal-kyl-, arylalkyl-, heteroarylalkyl-, alkyl-, f I uo ral kyl rad i kal, som har fra 1 til 5 car-bonatomer, cycloalkyl- eller cycloalkylalkylradikal, en -CH2COOR18-gruppe, hvor R18 står for et alkylradikal med 1 til 5 carbonatomer, eller også når R16 og R17 er bundet til det samme nitrogenatom, danner de en heterocyklus med mellem 3 og 7 led og omfatter eventuelt et eller to hete-roatomer, der er udvalgt blandt oxygen, svovl og nitrogen ud over det fælles nitrogenatom, til hvilket de er bundet, hvor heterocyklussen kan substitueres med en alkylgruppe med 1 til 5 carbonatomer eller en -COOR18-gruppe, hvor R18 står for et alkylradikal med 1 til 5 carbonatomer; X og X', identiske eller forskellige, står for et oxygenatom, et svovlatom eller et nitrogenatom, der er substitueret med et radikal R6, Y står for et oxygenatom, et svovlatom eller et nitrogenatom, der er substitueret med et radikal R15, og Z står for et carbon- eller nitrogenatom.
    1. Disubstituerede 3,4-diamino-3-cyclobuten-1,2-dion-forbindelse, som svarer til den følgende almene formel (I) eller et af sine farmaceutisk acceptable salte eller solvater:
    (i) hvor R1 står for et hydrogenatom eller en methyl, R2 står for en cyklus med fem atomer, der er udvalgt blandt de følgende strukturer (1), (2), (3) og (4):
  2. 2. Forbindelser ifølge krav 1, kendetegnet ved, at i den ovennævnte formel (I): R1 står for et hydrogenatom, R2 står for en cyklus med fem led, der er udvalgt blandt de følgende strukturer (1), (2) og (3):
  3. 3. Forbindelse ifølge krav 1 eller 2, kendetegnet ved, at i den førnævnte formel (I): R1 står for et hydrogenatom, R2 står for en cyklus med fem atomer med den følgende struktur (1):
  4. 4. Farmaceutisk sammensætning, omfattende en virksom mængde af en forbindelse eller et farmaceutisk acceptabelt salt af forbindelsen ifølge krav 1 i kombination med et farmaceutisk acceptabelt opløsningsmiddel eller en farmaceutisk acceptabel bærer.
  5. 5. Forbindelse ifølge krav 1 eller farmaceutisk sammensætning ifølge krav 4 til anvendelse som lægemiddel.
  6. 6. Forbindelse ifølge krav 1 eller farmaceutisk sammensætning ifølge krav 4 til anvendelse i behandlingen af sygdomme, som formidles af a-chimiokiner, der er udvalgt blandt sygdommene af gruppen, som omfatter neutrophile dermatoser, der er udvalgt blandt psoriasis, atopiske dermatider, akne, rosacea, astma, kronisk-obstruktive lungesygdomme, luftvejssygdomme hos voksne, artritis, inflammatoriske tarmsygdomme, Crohns sygdom, transplantatafstødning, cystisk fibrose og hudkræftstyper.
  7. 7. Forbindelse eller farmaceutisk sammensætning ifølge krav 6 til anvendelse i behandlingen af dermatologiske sygdomme, omfattende neutrophile dermatoser, der er udvalgt blandt psoriasis, atopiske dermatider, akne og rosacea.
  8. 8.
  9. Forbindelse ifølge krav 1, der er udvalgt fra listen, som omfatter: 1/- 2-hydroxy-N,N-dimethyl-3-(2-{[(5-methyl-furan-2-yl)-(2-methyl- tetrahydrofuran-2-yl)-methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)- benzamid 2/-2-hydroxy-/V,A/-dimethyl-3-(2-{[(5-methyl-furan-2-yl)-(tetrahydro-thiophen- 2-yl)-methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)-benzamid 3/- (S)-1-[2-fluoro-3-(2-{[(5-methyl-furan-2-yl)-(tetrahydro-thiophen-2-yl)- methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)-benzoyl]-pyrrolidine-2- carbonsyremethylester 4/- (S)-1-[2-fluoro-3-(2-{[(5-methyl-furan-2-yl)-(tetrahydro-thiophen-2-yl)- methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)-benzoyl]-pyrrolidin-2- carbonsyreisopropylester 5/- (S)-1-[2-fluoro-3-(2-{[(5-methyl-furan-2-yl)-(tetrahydro-thiophen-2-yl)- methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)-benzoyl]-pyrrolidin-2- carbonsyreethylester 6/- (R)-1-[2-hydroxy-3-(2-{[(5-methyl-furan-2-yl)-(tetrahydro-thiophen-2-yl)- methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)-benzoyl]-pyrrolidin-2- carbonsyremethylester 7/- (S)-1-[2-hydroxy-3-(2-{[(5-methyl-furan-2-yl)-(tetrahydro-thiophen-2-yl)- methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)-benzoyl]-pyrrolidin-2- carbonsyremethylester 8/- 2-hydroxy-N-methyl-3-(2-{[(S)-(5-methyl-furan-2-yl)-tetrahydro-thiophen-2- yl-methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)-N-(2,2,2-trifluoro-ethyl)- benzamid 9/- {[2-hydroxy-3-(2-{[(5-methyl-furan-2-yl)-(tetrahydro-thiophen-2-yl)-methyl]- amino}-3,4-dioxo-cyclobut-1-enylamino)-benzoyl]-methyl-amino}- eddikesyremethylester 10/- 6-chloro-2-hydroxy-N,N-dimethyl-3-(2-{[(5-methyl-furan-2-yl)-(tetrahydro- thiophen-2-yl)-methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)- benzolsulfonamid 11/-2-hydroxy-N,N-dimethyl-3-(2-{[(R)-(5-methyl-furan-2-yl)-tetrahydro-furan- 2-yl-methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)-benzamid 12/- 2-hydroxy-N,N-dimethyl-3-(2-{[(S)-(5-methyl-furan-2-yl)-tetrahydro-furan- 2- yl-methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)-benzamid 13/- 3-(3,4-dioxo-2-{[phenyl-(tétrahydrofuran-2-yl)-méthyl]-amino}-cyclobut-1 -enyl-amino)-2-hydroxy-N,N-dimethylbenzamid 14/- 3-(2-{[((R)-2,2-dimethyl-[1,3]dioxolan-4-yl)-(5-methyl-furan-2-yl)-methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)-2-hydroxy-N,N-dimethylbenzamid 15/ (S)-1 -[2-Fluoro-3-(2-{[(5-methyl-furan-2-yl)-(tetrahydro-thiophen-2-yl)-methyl]-amina}-3,4-dioxo-cyclobut-1-enylamino)-benzoyl]-pyrrolidin-2-carbonsyremethylester 16/ 3-(2-hydroxy-pyridin-3-ylamino)-4-{[(5-methyl-furan-2-yl)-(tetrahydro- thiophen-2-yl)-methyl]-amino}-cyclobut-3-en-1,2-dion 17/ 3-{[(5-methyl-furan-2-yl)-(tetrahydro-thiophen-2-yl)-methyl]-amino}-4-(1 - methyl-2-oxo-1,2-dihydro-pyridin-3-ylamino)-cyclobut-3-en-1,2-dion 18/ (-)-2-hydroxy-N-methyl-3-(2-{[(S)-(5-methyl-furan-2-yl)-(tetrahydro- thiophen-2-yl)-methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)-N-(2,2,2- trifluoro-ethyl)-benzamid 19/(-)-{[2-hydroxy-3-(2-{[(S)-(5-methyl-furan-2-yl)-(tetrahydro-thiophen-2-yl)- methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)-benzoyl]-methyl-amino}- eddikesyremethylester 20/ (-)-1-[2-hydroxy-3-(2-{[((S)-5-methyl-furan-2-yl)-(tetrahydro-thiophen-2- yl)-methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)-benzoyl]-pyrrolidin-2-(R)- carbonsyremethylester 21/(-)-6-chloro-2-hydroxy-N,N-dimethyl-3-(2-{[((S)-5-methyl-furan-2-yl)- (tetrahydro-thiophen-2-yl)-methyl]-amino}-3,4-dioxo-cyclobut-1-enylamino)- benzamid 22/(-)-3-[4-chloro-2-hydroxy-3-(4-methyl-piperazin-1-sulfonyl)-phenylamino]-4- {[(5-methyl-furan-2-yl)-(tetrahydro-thiophen-2-yl)-methyl]-amino}-cyclobut- 3- en-1,2-dion
DK12791825.8T 2011-10-28 2012-10-26 Nye disubstituerede 3,4-diamino-3-cyclobuten-1,2-dion-forbindelser til anvendelse i behandlingen af chemokin-formidlede sygdomme DK2771329T3 (da)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US201161552940P 2011-10-28 2011-10-28
FR1159833A FR2981935B1 (fr) 2011-10-28 2011-10-28 Nouveaux composes di-substitues de la diamino-3,4-cyclobutene-3-dione-1,2 utiles dans le traitement de pathologies mediees par des chimiokines.
PCT/FR2012/052478 WO2013061004A1 (fr) 2011-10-28 2012-10-26 Nouveaux composés di-substitués de la diamino-3,4-cyclobutène-3-dione-1,2 utiles dans le traitement de pathologies médiées par des chimiokines

Publications (1)

Publication Number Publication Date
DK2771329T3 true DK2771329T3 (da) 2016-06-06

Family

ID=45809111

Family Applications (1)

Application Number Title Priority Date Filing Date
DK12791825.8T DK2771329T3 (da) 2011-10-28 2012-10-26 Nye disubstituerede 3,4-diamino-3-cyclobuten-1,2-dion-forbindelser til anvendelse i behandlingen af chemokin-formidlede sygdomme

Country Status (24)

Country Link
US (2) US9388149B2 (da)
EP (1) EP2771329B1 (da)
JP (1) JP6068486B2 (da)
KR (1) KR20140090168A (da)
CN (1) CN103906738B (da)
AU (1) AU2012328198A1 (da)
BR (1) BR112014009889A2 (da)
CA (1) CA2848263A1 (da)
CY (1) CY1117705T1 (da)
DK (1) DK2771329T3 (da)
ES (1) ES2569053T3 (da)
FR (1) FR2981935B1 (da)
HR (1) HRP20160608T1 (da)
HU (1) HUE029128T2 (da)
IN (1) IN2014CN02273A (da)
MX (1) MX342924B (da)
PL (1) PL2771329T3 (da)
PT (1) PT2771329E (da)
RS (1) RS54775B1 (da)
RU (1) RU2014121390A (da)
SI (1) SI2771329T1 (da)
SM (1) SMT201600151B (da)
WO (1) WO2013061004A1 (da)
ZA (1) ZA201401678B (da)

Families Citing this family (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN105960237B (zh) * 2013-12-02 2020-03-31 凯莫森特里克斯股份有限公司 Ccr6化合物
FR3030515B1 (fr) 2014-12-23 2017-01-20 Galderma Res & Dev Nouveaux composes antagonistes des recepteurs cxcr1 et cxcr2 aux chimiokines, et leur utilisation dans le traitement de pathologies mediees par des chimiokines
TWI734715B (zh) 2015-11-19 2021-08-01 美商卡默森屈有限公司 趨化因子受體調節劑
TWI724056B (zh) 2015-11-19 2021-04-11 美商卡默森屈有限公司 Ｃｘｃｒ２抑制劑
US10660909B2 (en) 2016-11-17 2020-05-26 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists
AU2018318075B2 (en) 2017-08-14 2023-04-13 Allergan, Inc. 3,4-disubstituted 3-cyclobutene-1,2-diones and use thereof
CA3087701A1 (en) * 2018-01-08 2019-07-11 Chemocentryx, Inc. Methods of treating generalized pustular psoriasis with an antagonist of ccr6 or cxcr2
WO2019165315A1 (en) 2018-02-23 2019-08-29 Syntrix Biosystems Inc. Method for treating cancer using chemokine antagonists alone or in combination
GEP20237476B (en) 2018-09-21 2023-03-27 Pfizer N-substituted-dioxocyclobutenylamino-3-hydroxypicolinamides useful as ccr6 inhibitors
WO2021219849A1 (en) 2020-04-30 2021-11-04 Idorsia Pharmaceuticals Ltd Azetidin-3-ylmethanol derivatives as ccr6 receptor modulators
WO2023057548A1 (en) 2021-10-07 2023-04-13 Idorsia Pharmaceuticals Ltd Ccr6 receptor modulators
CN118215662A (zh) 2021-10-26 2024-06-18 爱杜西亚药品有限公司 Ccr6受体调节剂
IL312369A (en) 2021-10-28 2024-06-01 Idorsia Pharmaceuticals Ltd CCR6 receptor modulators

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6652737B2 (en) * 2000-07-21 2003-11-25 Exxonmobil Research And Engineering Company Production of naphtha and light olefins
CZ20032831A3 (cs) * 2001-04-16 2004-03-17 Schering Corporation 3,4-Disubstituované cyklobuten-1,2-diony
EP2155670B1 (en) * 2007-06-06 2012-04-18 Novartis AG Anti -inflammatory substituted cyclobutenedione compounds
UA103198C2 (en) * 2008-08-04 2013-09-25 Новартис Аг Squaramide derivatives as cxcr2 antagonists
KR200444641Y1 (ko) * 2008-12-03 2009-05-27 강민수 헤드작동형 다기능 스패너
WO2010063802A1 (en) * 2008-12-05 2010-06-10 Novartis Ag 3, 4-di-substituted cyclobutene- 1, 2 -diones as cxcr2 receptor antagonists
WO2010131146A1 (en) * 2009-05-12 2010-11-18 Pfizer Limited Cyclobutenedione derivatives

Also Published As

Publication number Publication date
MX342924B (es) 2016-10-19
WO2013061004A1 (fr) 2013-05-02
AU2012328198A1 (en) 2014-04-03
CY1117705T1 (el) 2017-05-17
MX2014003958A (es) 2014-08-27
PT2771329E (pt) 2016-06-17
US20140296254A1 (en) 2014-10-02
SI2771329T1 (sl) 2016-07-29
HRP20160608T1 (hr) 2016-07-01
US20160362403A1 (en) 2016-12-15
HUE029128T2 (en) 2017-02-28
CA2848263A1 (fr) 2013-05-02
PL2771329T3 (pl) 2016-09-30
SMT201600151B (it) 2016-07-01
RS54775B1 (sr) 2016-10-31
ES2569053T3 (es) 2016-05-06
CN103906738A (zh) 2014-07-02
ZA201401678B (en) 2015-04-29
EP2771329A1 (fr) 2014-09-03
JP6068486B2 (ja) 2017-01-25
US9580412B2 (en) 2017-02-28
WO2013061004A8 (fr) 2014-04-17
EP2771329B1 (fr) 2016-03-16
IN2014CN02273A (da) 2015-06-19
JP2014530894A (ja) 2014-11-20
FR2981935A1 (fr) 2013-05-03
FR2981935B1 (fr) 2015-08-07
KR20140090168A (ko) 2014-07-16
BR112014009889A2 (pt) 2017-04-25
US9388149B2 (en) 2016-07-12
CN103906738B (zh) 2016-09-07
RU2014121390A (ru) 2015-12-10

Similar Documents

Publication Publication Date Title
DK2771329T3 (da) Nye disubstituerede 3,4-diamino-3-cyclobuten-1,2-dion-forbindelser til anvendelse i behandlingen af chemokin-formidlede sygdomme
US9090596B2 (en) Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated pathologies
US9415039B2 (en) Disubstituted 3,4-diamino-3-cyclobutene-1,2-dione compounds for use in the treatment of chemokine-mediated diseases
US5856323A (en) Compounds and methods for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
DE60007267T2 (de) 4,5-diaryl-3(2h)-furanon derivate als cyclooxygenase-2 inhibitoren
US5780503A (en) Compounds and methods for the treatment of cardiovascular, inflammatory and immune disorders
JP2013537899A (ja) クロメン誘導体
US5530141A (en) 2,4-diaryl-1,3-dithiolanes; 2,4-diaryl-1,3-dioxolanes; 2,4-diaryl-1,3-oxathiolanes; and 2,5-diaryl-1,3-oxathiolanes for the treatment of disorders mediated by platelet activating factor or products of 5-lipoxygenase
CN116925064A (zh) 合成小分子il-17a调节剂的方法
CN116925060A (zh) 合成小分子il-17a调节剂的方法
RU2574164C2 (ru) Производные хромена
Yang et al. Synthesis and crystal structure of 6-trichloromethyl-9-oxa-5-azatricyclo [6.2. 1.01, 5] undecan-10-one